| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
140,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic Chimeric antigen receptor (CAR) T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. Co. is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma, and other blood cancers and solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
190 |
190 |
190 |
| Total Buy Value |
$0 |
$683 |
$683 |
$683 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
18,640 |
28,640 |
82,742 |
| Total Sell Value |
$0 |
$50,317 |
$93,172 |
$700,150 |
| Total People Sold |
0 |
1 |
2 |
5 |
| Total Sell Transactions |
0 |
1 |
2 |
12 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Moore Alison |
Chief Technical Officer |
• – – |
2020-10-06 |
4 |
AS |
$40.00 |
$1,782,960 |
D/D |
(44,574) |
117,680 |
|
- |
|
| Moore Alison |
Chief Technical Officer |
• – – |
2020-10-06 |
4 |
OE |
$2.27 |
$80,049 |
D/D |
35,264 |
161,536 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2020-10-06 |
4 |
AS |
$40.00 |
$400,000 |
D/D |
(10,000) |
353,902 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2020-10-06 |
4 |
OE |
$2.27 |
$22,700 |
D/D |
10,000 |
363,902 |
|
- |
|
| Amado Rafael |
EVP of R&D and CMO |
• – – |
2020-10-01 |
4 |
S |
$36.37 |
$354,662 |
D/D |
(9,752) |
128,215 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2020-10-01 |
4 |
AS |
$36.21 |
$912,913 |
D/D |
(25,000) |
353,902 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2020-10-01 |
4 |
OE |
$2.27 |
$56,750 |
D/D |
25,000 |
378,902 |
|
- |
|
| Schmidt Eric Thomas |
Chief Financial Officer |
• – – |
2020-09-21 |
4 |
AS |
$34.76 |
$529,545 |
I/I |
(15,000) |
1,212,595 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2020-09-01 |
4 |
AS |
$35.35 |
$883,966 |
D/D |
(25,000) |
353,902 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2020-09-01 |
4 |
OE |
$2.27 |
$56,750 |
D/D |
25,000 |
378,902 |
|
- |
|
| Chang David D |
President and CEO |
• • – |
2020-08-31 |
4/A |
GA |
$0.00 |
$0 |
I/I |
411,556 |
856,044 |
|
- |
|
| Moore Alison |
Chief Technical Officer |
• – – |
2020-08-13 |
4 |
OE |
$2.27 |
$73,664 |
D/D |
32,451 |
126,272 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-08-07 |
4 |
AS |
$37.02 |
$497,236 |
I/I |
(13,291) |
18,716,306 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-08-06 |
4 |
AS |
$37.33 |
$905,794 |
I/I |
(24,154) |
18,729,597 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-08-06 |
4 |
AS |
$0.00 |
$0 |
I/I |
(962,555) |
18,753,751 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2020-08-03 |
4 |
AS |
$36.46 |
$1,164,121 |
D/D |
(31,553) |
353,902 |
|
- |
|
| Bhavnagri Veer |
General Counsel |
• – – |
2020-08-03 |
4 |
OE |
$2.27 |
$56,750 |
D/D |
25,000 |
385,455 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-25 |
4 |
S |
$44.19 |
$3,197,327 |
I/I |
(72,359) |
19,801,457 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-24 |
4 |
S |
$43.93 |
$670,714 |
I/I |
(15,269) |
19,873,816 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-23 |
4 |
S |
$43.91 |
$5,814,610 |
I/I |
(132,225) |
19,889,085 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-22 |
4 |
S |
$42.72 |
$7,384,721 |
I/I |
(172,425) |
20,021,310 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-19 |
4 |
S |
$42.04 |
$2,008,306 |
I/I |
(47,767) |
20,193,735 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-18 |
4 |
S |
$42.14 |
$3,986,595 |
I/I |
(94,600) |
20,241,502 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-17 |
4 |
S |
$42.18 |
$3,683,482 |
I/I |
(87,319) |
20,336,102 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2020-06-16 |
4 |
S |
$42.20 |
$7,364,678 |
I/I |
(174,511) |
20,423,421 |
|
- |
|
103 Records found
|
|
Page 3 of 5 |
|
|
